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1. Introduction 
Critical limb ischemia due to chronic peripheral arterial occlusive disease, such as 
arteriosclerosis obliterans and Buerger’s disease (thromboangiitis obliterans), damages 
peripheral nerves and results in an ischemic neuropathy. Clinical and electro-physiologic 
features of ischemic neuropathy are sensorimotor polyneuropathy with axonal features as 
previously reported. In particular, symptoms of ischemic neuropathy include painful 
burning, sensory impairment, and reflex loss. Although ischemic peripheral neuropathy is a 
major complication of critical limb ischemia resulting in impaired quality of life, effective 
treatment for ischemic neuropathy is not available at present. 
Recently, it has been reported that therapeutic angiogenesis using vascular endothelial 
growth factor (VEGF) gene transfer for critical limb ischemia improves ischemic neuropathy 
in animals or humans. Furthermore, Cuevus et al. reported that transplantation of bone 
marrow stromal cells improved peripheral nerve function in rats. 
We reported that therapeutic angiogenesis using autologous transplantation of bone 
marrow mononuclear cells (BM-MNCs) for peripheral artery disease increased limb 
perfusion and improved clinical conditions, such as ischemic pain, claudication and 
ischemic ulcer. BM-MNCs contain various kinds of cell lineages, such as CD34+ cells or bone 
marrow stromal cells, in addition to various growth factors, such as VEGF. Thus, such cells 
or growth factors can work beneficially for ischemic peripheral neuropathy.  
Therefore, in this chapter, we tried to clarify whether cell therapy with autologous 
transplantation of BM-MNCs improves ischemic neuropathy with critical ischemic limb in 
humans. 
2. Patients and methods 
2.1 Study subjects 
We prospectively examined 39 patients having chronic bilateral critical limb ischemia, defined 
as angiographic documentation of severe large artery stenosis or occlusion associated with 
limb pain at rest and/or non-healing ischemic ulcers. All the patients fulfilled the inclusion 
criteria and did not have any exclusion criteria for therapeutic angiogenesis using BM-MNCs 
as described previously. Briefly, they were not candidates for non-surgical or surgical 
revascularization. We excluded patients with poorly controlled diabetes mellitus 
(HbA1C>6.5% and proliferative retinopathy) or with evidence of malignant disorder for the 
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past 5 years. Furthermore, patients in whom neurological scales could not be evaluated due to 
huge ulcer or limb amputation were excluded. Finally, 14 patients undergoing autologous 
transplantation of BM-MNCs were enrolled in this study. Age and sex matched 23 healthy 
volunteers were served as controls to examine neurophysiologic scales (Healthy group). The 
protocol was approved by the Institutional Ethic Committee of the Kurume University. 
Written informed consent was obtained from all subjects. 
2.2 Collection and transplantation of BM-MNCs 
Bone marrow cells were collected from the iliac crest under general anesthesia. We sorted 
mononuclear cells on CS-3000 blood-cell separator (Baxter, Deerfield, USA) by a density 
gradient centrifugation method and concentrated them to a final volume of about 30ml 
immediately after aspiration. We injected the cells with 26-gauge needle into the gastro-
cunemius muscle of the more ischemic limb (treated limb), and injected saline into the 
opposite limb (control limb). We injected about 0.5ml of BM-MNCs or saline into each 
injection site (50 sites, 1-1.5cm deep).  
2.3 Clinical features 
The severity of rest pain was described and scored by patient from 0 (none) to 10 
(maximum) points using visual analogue scale (VAS). Pain free walking distance was 
separately measured twice as ischemic status before and 4 weeks after transplantation of 
BM-MNCs. Also, the detailed nature of pain was recorded to exclude symptoms that could 
be attributable to tissue ischemia rather than neuropathy. To distinguish neuropathic 
symptoms from ischemic ones, numbness, painful burning, and paresthesia in the toes of 
foot were defined neuropathic in origin. We excluded symptoms when they exclusively 
appeared during walk or by use (i.e. foot elevations). Two examiners evaluated the 
neurological scales. The examiners were blinded to the findings of patients’ clinical profile, 
treatment and to each other’s results. The existence of neuropathic symptom was described 
and scored by the patient from 0 to 1 point (0=without neuropathic symptom, 1=with 
neuropathic symptom) as neurologic sensory score (NSS). We tested untreated limb to 
assess the natural course of the disease as control limb. Each patient was evaluated 1 week 
before and 4 weeks after treatment. 
2.4 Neurophysiologic scales 
Two examiners evaluated the neurological scales. The examiners were blinded to the findings 
of patients’ clinical profile, treatment and to each other’s assessment. Conduction studies were 
performed using techniques described elsewhere (Neuropack MEB-2200, Nihon Kohden Co. 
ltd, Japan). Briefly, motor nerve conduction velocities (MNCV) of the tibial nerve were 
measured. Tibial compound muscle action potentials (CMAP) were also recorded with surface 
disk electrodes from the abductor hallucis. Sensory nerve conduction velocities (SNCV) or 
sensory nerve action potentials (SNAP) of the sural nerve were measured. All determinations 
were made with the patient supine and at the surface temperature between 29-32°C. The same 
examiner using the identical anatomical landmarks and distances performed repeated studies 
after treatment. Quantitative vibration threshold time (QVT) was measured using standard 
techniques by a tuning fork to determine the thresholds of vibration in the legs. We performed 
these neurophysiologic testing before and 4 weeks after treatment. We also measured MNCV, 
SNCV, CMAP and SNAP of the healthy group at baseline. 
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2.5 Assessment of blood flow 
We measured ankle brachial pressure index (ABPI) 1 week before and 4 weeks after 
implantation, the ratio of simultaneously measured systolic pressure of brachial and 
posterior tibial arteries (ABI-form, Colin, Japan). Digital subtraction angiography (DSA) was 
performed with the strictly fixed amount of contrast agent, force of contrast injection, and 
position of the catheter tip at 1 week before and 4 weeks after transplantation. Two 
radiologists who were blinded to treatment evaluated collateral vessels independently. 
Angiograms were assessed when contrast flow in the main conducting arteries was most 
clearly visible. Angiographic evaluation was presented as changes in DSA score: 3+ (rich 
collateral development), 2+ (moderate), 1+ (slight), 0 (no changes), and 1- (decreased).  
2.6 Statistical analysis 
Data were expressed as mean ± SD. Differences between the two groups were analyzed by 
paired or unpaired Student’s t test when appropriate. Univariate correlations were analyzed 
by a Pearson’s correlation. Differences with a p< 0.05 were considered statistically 
significant. 
3. Results 
3.1 Patient’s characteristics 
Patient’s characteristics are shown in Table 1. Nine patients were Buerger’s disease and 5 
ASO. They all had undergone optimal medical or surgical treatment prior to this study. The 
average numbers of transplanted mononuclear cells of CD34 positive cells were 
4.89±5.21x109 and 5.46±4.25x107, respectively (Table 1). During follow up period, no one had 
major adverse event, such as any cause of death and cardiovascular event. 
 
Patient Age (y.o.) sex Diagnosis 
No. of 
MNCs 
(x109) 
No. of 
CD34+ cells 
(x107) 
1 67 M TAO 2.58 2.63 
2 29 M TAO 2.9 8.48 
3 72 F TAO 1.07 0.92 
4 69 M ASO 1.83 6.82 
5 43 M TAO 4.14 7.18 
6 63 M ASO 1.39 1.17 
7 75 M ASO 1.70 5.03 
8 40 M TAO 5.12 17.05 
9 61 M TAO 13.5 3.3 
10 50 M TAO 16.90 6.5 
11 62 M TAO 11.9 8.3 
12 78 M ASO 1.80 2.9 
13 55 F TAO 2.38 5.1 
14 65 F ASO 1.20 1.1 
mean±SD 59.2±14.2   4.89±5.21 5.46±4.25 
Abbreviations y.o.: years old, M: male, F: female, MNCs: mononuclear cells, TAO: thromboangiitis 
obliterans, ASO: arteriosclerosis obliterans 
Table 1. Patients characteristics and number of implanted cells. 
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Fig. 1. Neurologic sensory score. 
 
 
Panel A: Visual analogue scale significantly decreased one month after autologous transplantation of 
BM-MNCs.  
Panel B: Pain free walking time significantly increased one month after autologous transplantation of 
BM-MNCs. 
Open circles indicate individual value. Closed circle indicate average value. 
Fig. 2. Improvement of ischemic symptoms. 
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3.2 Subjective symptoms 
Before treatment, 10 of 14 patients (71.4%) had neuropathic symptoms with average NSS of 
0.71±0.47 (Figure 1). Four weeks after treatment, only 2 patients had neuropathic symptoms, 
and averaged NSS was decreased to 0.14±0.36 (p<0.01 vs. before treatment, Figure 1). VAS 
significantly improved (3.93±3.92 to 0.79±1.79, p<0.01, Figure 2A) after treatment. Pain free 
walking distance significantly increased (201±110 to 317±197, P<0.05, Figure 2B) after 
treatment 
3.3 Nerve functions  
MNCV and CMAP could be measured in the treated limb of all patients, and in the control 
limb of 12 patients. SNCV and SNAP could be measured 11 of 14 patients in the treated 
limb, and 10 of 14 patients in the control limb. Figure 3 shows the representative waveform 
of MNCV and CMAP before and one month after treatment. Before treatment, both MNCV 
and CMAP were significantly smaller in the treated limb than those in the healthy group 
(Table 2). Treatment significantly increased both MNCV and CMAP only in the treated limb 
(Table 2) but not in the control limb. MNCV was recovered to the level of healthy group but 
CMAP was still depressed after transplantation of BM-MNCs (Table 2). SNCV and SNAP of 
the patients did not differ to those of the healthy group. SNCV and SNAP were not 
improved by treatment (Table 2). QVT was significantly improved only in the treated limb, 
but not in the control limb after treatment (Table 2). 
 
 
Fig. 3. Representative waveforms of MNCV and CMAP. MNCV and CMAP increased one 
month after autologous transplantation of BM-MNCs.  
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Healthy 
group 
N=23 
Patients 
N=14 
Nerve 
function 
 before after before after 
  Control limb Treated limb 
MNCV 
(m/sec) 
50.4±6.94 47.3±3.0 44.8±3.0 41.1±6.5** 43.9±6.2 
CMAP (mV) 5.3±2.8 4.9±4.3 5.2±5.2 2.3±2.7* 3.6±3.5¶* 
SNCV 
(m/sec) 
50.0±10.7 49.5±3.7 48.3±4.5 46.8±4.3 46.5±4.9 
SNAP (µV) 10.2±8.9 8.4±2.1 8.6±3.1 7.6±3.8 8.7±4.4 
QVT (sec) NM 10.5±3.2 11.1±4.0 9.2±2.7 11.5±3.5 
Values are expressed as mean±SD. Differences between the two groups were analyzed by paired or 
unpaired Student’s t test. Univariate correlations were analyzed by a Pearson’s correlation. 
Abbreviations VAS: visual analogue scale, MNCV: motor nerve conduction velocity, CMAP: compound 
muscle action potential, SNCV: sensory nerve conduction velocity, SNAP: sensory nerve action 
potential, QVT: quantitative vibration threshold time. N/A: not available, NM: not measured, SD: 
standard deviation 
*: p<0.05 vs. healthy group, **: p<0.01 vs. healthy group, ¶: p<0.05 vs. before treatment, :p<0.01 vs. 
before treatment. 
Table 2. Effects of nerve functions. (Based on data originally presented by Arima, K. et al.). 
3.4 Assessment of blood flow 
Before treatment, ABPI was significantly decreased in the treated and control limbs. After 
treatment, ABPI was significantly increased only in the treated limb (0.59±0.24 to 0.70±0.20, 
P=0.035), but not in the control limb (0.89±0.20 to 0.89±0.20, N.S.). DSA score in the treated 
limb was significantly increased after treatment (0.0±0.0 to 0.86±0.77, p<0.05, Figure 4). 
4. Discussion 
The major findings of this study are the following two. First, autologous transplantation of 
BM-MNCs significantly improved subjective ischemic and neuropathic symptoms in 
patients with critical limb ischemia. Second, autologous transplantation of BM-MNCs 
improved not only peripheral blood perfusion but also peripheral nerve function. 
4.1 Neuropathy in patients with critical limb ischemia 
Several studies have reported neuropathy at the frequency of 5-31% in patients with chronic 
and critical limb ischemia. The mechanisms of neuropathy in patients with limb ischemia 
are multifocal because they have frequently have associated disease like diabetes mellitus. 
Weinberg et al reported that the degree of ischemia, as estimated with ABPI, correlated with 
clinical neuropathy. Thus it is suggested that limb ischemia is the major factor of peripheral 
neuropathy in patients with critical limb ischemia.  
www.intechopen.com
 
Cell Therapy for Ischemic Peripheral Neuropathy 
 
185 
 
Fig. 4. Time course of DSA score after autologous transplantation of BM-MNCs in the 
treated limb. In the treated limb, DSA score significantly improved one month after 
autologous transplantation of BM-MNCs (P<0.05). DSA indicates digital subtraction 
angiography. 
In this study, our patients had not only ischemic symptoms (rest pain and claudication) but 
also neuropathic symptoms. Because ABPI was significantly decreased and because we 
excluded patients with diabetes mellitus, we think the nature of neuropathic symptoms is 
related to limb ischemia. Furthermore, nerve function in the patients was severely impaired 
compared with the healthy group. Thus, the etiology of peripheral neuropathy in our 
patients was probably ischemic in its origin. Although our patients had bilateral limb 
ischemia, the nerve function at baseline was impaired only in the treated limb. The reason is 
not clear at present but the difference in the severity of limb ischemia may explain it. 
Apart from MNCV or CMAP, SNCV and SNAP of ischemic limb before treatment were 
similar to those of healthy subject. The reason of such different effect of limb ischemia on 
motor and sensory nerves is unknown, but may be due to the size of nerve fibers. The size of 
motor nerve (5-15 micrometer) is larger than sensory nerve (0.5-13 micrometer). Previous 
pathologic studies reported that decrease in the population of large myelinated fibers was 
observed in ischemic peripheral neuropathy. The damage of nerve fiber may be smaller for 
the sensory nerve than the large motor nerve in the presence of ischemia, which may 
account for the preserved SNCV and SNAP.  
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4.2 Autologous transplantation of BM-MNCs improved neuropathy 
Recently, we reported that autologous transplantation of BM-MNCs increased limb 
perfusion and improved symptoms and ulcers in human ischemic limb. In this study, we 
confirmed our previous findings that autologous transplantation of BM-MNCs significantly 
improved ABPI and DSA score in treated limbs. This treatment significantly improved not 
only ischemic pain (VAS, pain free walking time) but also neuropathic symptoms. 
Furthermore, transplantation of BM-MNCs significantly improved objective peripheral 
nerve functions (MNCV, CMAP and QVT) in the treated limb, but saline injection did not 
affect the nerve functions. These results indicated that the effects of the treatment were not 
related to natural course or non-specific effects. Thus, it is concluded that autologous 
transplantation of BM-MNCs improved not only peripheral blood perfusion but also 
ischemic peripheral neuropathy. 
4.3 Mechanisms of improvement of peripheral neuropathy 
The several mechanisms may contribute to the improvement of peripheral nerve function. 
First, the improvement may be caused by better blood perfusion after autologous 
transplantation of BM-MNCs. On this issue several conflicting results were reported.  
There were several therapeutic strategies for improving blood perfusion, such as surgical 
revascularization or therapeutic angiogenesis induced by VEGF gene transfer. Hunter et al. 
examined electrophysiological changes of nerves after surgical revascularization. They 
reported no improvement of multiple electrophysiological outcome measures after surgical 
revascularization, suggesting that ischemic neuropathy may be an irreversible condition. On 
the other hand, Simovic et al. reported that VEGF gene transfer improved the neuropathic 
symptoms, CMAP and QVT, but not nerve conduction velocity. They speculated that the 
differences of efficiency between surgical revascularization and VEGF gene transfer were 
related to the size of restored vessels after treatments. In fact, surgical revascularization 
mainly restores blood flow of large vessels, and neovascularization from angiogenic 
cytokines, such as VEGF, principally involves small vessels including the vasa-nervorum 
(<180 micrometer), the nutrient arteries of peripheral nerves. Furthermore, it is reported that 
VEGF gene transfer improves peripheral nerve perfusion and function through regeneration 
of vasa-nervorum in rats with streptozotocin-induced diabetes. In this study, 
electrophysiological study showed improvement of nerve functions in addition to 
neuropathic symptoms. It is reported that variety of cytokines, such as VEGF, are contained 
in transplanted bone-marrow fluid or secreted by transplanted BM-MNCs. Thus, such 
various angiogenic cytokines might have improved nerve perfusion and function in this 
study. 
Second, nerve regeneration might have occurred after transplantation of BM-MNCs. It is 
reported that VEGF also has regenerative and protective function for peripheral nerve. 
Furthermore, Cuevas et al. reported that implantation of bone-marrow stromal cells 
improved peripheral nerve function via nerve regeneration in animals. They reported that 
implanted cells participated in nerve regeneration through their differentiation in Schwann-
like cells and also in the production of trophic factors. Because transplanted BM-MNCs used 
in this study presumably contain various kinds of cells such as bone-marrow stromal cells as 
previously reported, it may be speculated that transplantation of BM-MNCs might have 
regenerated the damaged peripheral motor nerve. Of course, we have no evidence. 
Limitations of this study need to be addressed. First, this study was an observational open-
label study with no placebo control group. Next, the number of patients enrolled in this 
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study was small. Further large sized controlled clinical study is needed to confirm our 
findings. Finally, we treated patients with critical limb ischemia who had undergone 
optimal medical and surgical treatment. Thus, it is not known whether autologous 
transplantation of BM-MNCs is effective for the earlier stage of patients.  
5. Conclusions 
In conclusion, these results suggested that cell therapy with autologous transplantation of 
BM-MNCs improves ischemic neuropathy with critical ischemic limb in humans. 
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